Navidea Biopharma (NYSE: NAVB) reported Q2 EPS of ($0.11), versus ($0.24) reported last year. Revenue for the quarter came in at $271 thousand versus the consensus estimate of $156 thousand.

“The past four months have been truly momentous for the company. The successful second interim look showed how valuable our diagnostic agent will be for the effective management of Rheumatoid Arthritis,” said Mr. Jed A. Latkin, Chief Executive Officer of Navidea. “The signing of the binding MOU with Jubilant is a transformational event for the future of Navidea. Partnering with the second largest radiopharmaceutical company in the United States and a global leader in pharmaceuticals is something we have worked hard to achieve for many years. Furthermore, the $25 million in growth capital pledged by a top-notch syndicate of investors has assured the company’s non-RA related growth funding for years to come.”

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.